This disclosure provides methods and compositions for improving the genome modification efficiency of programmable DNA modification proteins during transfection (e.g., electroporation).
Heterobifunctional chemical linkers useful in protein degraders and other medicinal chemistry applications are provided. The heterobifunctional linkers include alky ne-piperidine and alkane-piperidine linkers: alkane-piperazine linkers; alkanamino PEGylated linkers; dipiperazine linkers; piperazine-pyridine/pyrimidine-alkyne linkers; pyridine-PEG-piperazine linkers and pyrimidine-piperazine-PEG linkers. Also provided are combinations of the provided linkers with a ligand that targets a degradation pathway, such as an E3 ubiquitin ligase enzyme.
C07D 295/205 - Radicaux dérivés de l'acide carbonique
C07D 295/215 - Radicaux dérivés d'analogues azotés de l'acide carbonique
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
3.
METABOLIC SELECTION VIA THE ALANINE BIOSYNTHESIS PATHWAY
The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Glutamic-Pyruvic Transaminase 2 (GPT2). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.
Targeting liposomes for protein degrader delivery. In one embodiments, the targeting liposome including a phospholipid, a cholesterol or cholesterol derivative, a PEG lipid, a targeting lipid; and a protein degrader. In other embodiments, the targeting liposome including a phospholipid, a cholesterol or cholesterol derivative, a PEG lipid, a targeting lipid; and a protein degrader- ligase complex. Also provided are kits for preparing targeting liposomes for protein degrader and/or protein degrader-ligase complexes. Also provided are methods for preparing such targeting liposomes.
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Intermediates useful in the preparation of exatecan mesylate and related compounds. Further provided are methods for preparing these compounds. Also provided is an improved, scalable synthesis of exatecan mesylate using the provided intermediates. The synthesis of exatecan mesylate utilizes a convergent approach, involving fewer steps and utilizing fewer reagents and increasing efficiency.
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
6.
IMPROVED PRIME EDITING SYSTEM EFFICIENCY WITH CIS-ACTING REGULATORY ELEMENTS
The present invention is a synthetic nucleic acid composition comprising: i) a sequence encoding a CRISPR-Cas protein, ii) a sequence encoding a reverse transcriptase, and iii) a sequence encoding a cis-acting regulatory element, and methods of use thereof.
Provided are ferrocenyl-based phosphine compounds, which contain either (i) a di(adamantyl)phosphino group on a first cyclopentadienide ring and a penta-aryl substitution on a second cyclopentadienide ring, or (ii) a di(adamantyl)phosphino group on a first cyclopentadienide ring and a second cyclopentadienide ring, respectively. Further provided are scalable processes for synthesizing said ferrocenyl-based phosphine compounds starting from readily available starting materials with simple workup as well as various precatalysts containing a transition metal and said ferrocenyl- based phosphine compounds as ligands.
The present invention provides a plurality of oligonucleotides comprising a semi-random sequence, wherein the semi-random sequence comprises degenerate nucleotides that are substantially non-complementary. Also provided are methods for using the plurality of oligonucleotides to amplify a population of target nucleic acids.
Nuclear targeting tags having a phenylboronate targeting moiety, a linker, a chemically linkable end group suitable for linking the targeting moiety to a molecule of interest, and optionally a spacer between the linker and chemically linkable end group. Also provided are compounds including the nuclear targeting tag covalently bonded to a molecule of interest, such as a drug, probe, dye, peptide, protein, drug candidate, or natural product. Also provided are methods of introducing a molecule of interest into a nucleus of a cell using the nuclear targeting tag. Also provided are methods for preparing the nuclear targeting tags.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Ferrocenyl-based unsymmetrical ligands containing di(1-adamantyl)phosphino groups with general formula, Fc(Ad2P) (R2P) and corresponding metal complexes, include metal halide complexes, N-biphenyl metal cationic complexes and R-allyl metal cationic complexes, useful in catalysis. The ligands and complexes overcome problems with conventional catalysts, providing new routes to previously challenging cross-coupling reactions, including C—P coupling, Csp2—Csp3 coupling and other conventional cross-coupling applications, while being scalable so that they can be provided in sufficient quantity and purity for industrial applications.
The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Serine Hydroxymethyltransferase 2 (SHMT2). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.
Provided is an optimized process for the synthesis of palladium(O) phosphine complexes. The process described herein is characterized by a more efficient reaction control, high yield and purity, the use of readily available starting materials, and savings in reaction time and steps, thereby offering increased sustainability when compared to processes reported in the state of the art.
The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.
C08L 71/00 - Compositions contenant des polyéthers obtenus par des réactions créant une liaison éther dans la chaîne principaleCompositions contenant des dérivés de tels polymères
16.
METHODS FOR NEXT GENERATION GENOME WALKING AND RELATED COMPOSITIONS AND KITS
Methods are provided herein for identifying rare and/or unknown DNA sequences by next-generation sequencing approaches. Isolated double-stranded (ds), single-stranded (ss), or ds/ss DNA is fragmented and the fragments are polished, phosphorylated, and tailed, as necessary. Fragmentation can be enzymatic or mechanical. A universal adapter sequence is ligated to each fragment, wherein the adapter can have a top strand without a 5′ phosphate, a 3′ with an —H in place of the —OH, and/or a 3′ extra base complementary to any base added to the polished fragments. The ligatamers may then serve as templates for amplification using a forward primer complementary to the adapter sequence and a reverse primer targeted to the fragment sequence. Compositions produced by these methods and kits adapted for performing these methods are also described herein.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 20/04 - Identification des éléments d'une bibliothèque au moyen d'une étiquette, d'un marqueur ou d'un autre identificateur lisible ou détectable, p. ex. procédés de décodage
17.
MARKETPLACE FOR ENABLING SUSTAINABLE CHEMISTRY PRODUCTION PROCESSES
A method and a respective system for performing a chemical synthesis via a computer comprising the following steps of Defining a desired organic target molecule of the chemical synthesis to be produced in the chemical production plant; Providing information describing the desired organic target molecule to a software-based platform being hosted by a computer connected to a network, wherein the platform holds inventories of chemical suppliers and the inventories comprises of information about synthetic reagents, like by-products and/or waste, needed for the chemical synthesis; Routing the chemical synthesis via the computer, wherein the computer checks the inventories of the platform for the necessary synthetic reagents to perform the chemical synthesis to produce the target molecule by comparing the information describing the desired organic target molecule and the information in the inventories and connects those chemical suppliers to the chemical production plant which provide the most suitable synthetic reagents according to the compared information; and Producing the desired organic target molecule in the chemical production plant with the provided synthetic reagents from the chemical suppliers chosen by the computer of the software-based platform.
G16C 20/00 - Chémo-informatique, c.-à-d. TIC spécialement adaptées au maniement des données physicochimiques ou structurelles des particules, des éléments, des composés ou des mélanges chimiques
18.
PRE-COATINGS FOR BIOCOMPATIBLE SOLID PHASE MICROEXTRACTION DEVICES
An improved device for solid phase microextraction, the device including a plastic substrate, a pre-coating layer on the plastic substrate, and an SPME coating on the precoating layer. SPME coatings are typically incompatible with plastic substrates due to differences between the surface energies of the substrate and the coating, leading to uneven coating and poor adhesion. The addition of the precoating layer provides increased evenness and stronger adhesion of the SPME coating to the plastic substrate. Also provided are method of coating an SPME coating on a plastic substrate, the method including the step of precoating the plastic substrate to provide a precoated substrate and then coating the precoated substrate with an SPME coating, wherein precoating provides improved coating evenness and adhesion of the SPME coating to the plastic substrate.
Improved methods for drying for bio-compatible solid phase microextraction (BioSPME) coatings yielding coatings with highly consistent extraction efficiency and biocompatibility. The methods, adapted to flow-through drying systems involve determining relative humidity in and around the drying system, determining a drying temperature range based on the relative humidity, and maintaining the drying temperature within the determined range while drying the coating.
Methods for integrating exogenous sequences in genomic loci, wherein the integration is stable and the exogenous sequence can function predictably and reliably.
C07K 14/205 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Campylobacter (G)
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
22.
PYRROLOBENZODIAZEPINE INTERMEDIATES AND USES THEREOF
Pyrrolobenzodiazepine (PBD) intermediates, including useful in the preparation of advanced intermediates, PBDs, and PBD dimers. Such PBD intermediates provide several advantages, including simplified synthesis of desired PBD products, greater substrate compatibility, and safer reaction conditions.
The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Asparagine Synthetase (ASNS). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.
The disclosed and claimed subject matter relates to high-purity alkynes substantially free of residual alkyl halides, water and/or carboxylic acids and their use (e.g., in formulations) for enhanced passivation of metallic substrates.
C07C 11/22 - Hydrocarbures non saturés acycliques comportant des liaisons triples carbone-carbone
C23C 16/00 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD]
Heterobifunctional chemical linkers useful in protein degraders and other medicinal chemistry applications are provided. The heterobifunctional linkers include alkyne-piperidine and alkane-piperidine linkers; alkane- piperazine linkers; alkanamino PEGylated linkers; dipiperazine linkers; piperazine-pyridine/pyrimidine-alkyne linkers; pyridine-PEG-piperazine linkers and pyrimidine-piperazine-PEG linkers. Also provided are combinations of the provided linkers with a ligand that targets a degradation pathway, such as an E3 ubiquitin ligase enzyme.
C07D 295/205 - Radicaux dérivés de l'acide carbonique
C07D 295/215 - Radicaux dérivés d'analogues azotés de l'acide carbonique
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
Methods for making a dolastatin, auristatin or related compounds comprising the steps of providing a universal dolastatin core of Formula (I) reacting the C-terminal carboxylic acid group with an amine (A) to form an amide bond and reacting the N-terminal amine with a carboxylic acid (CA) to form an amide bond, wherein the steps can be performed in either order. Also provided are an isolated salt of the universal dolastatin core for use in preparation of dolastatins, auristatins and related compounds. Also provided are a number of intermediates and process steps which are useful for the preparation of high purity dolastatin core and high purity dolastatin and auristatin compounds.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
C07D 207/08 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés aux atomes de carbone du cycle
C07C 229/22 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé le squelette carboné étant substitué de plus par des atomes d'oxygène
C07C 271/22 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes carboxyle
28.
IMPROVED PRIME EDITING SYSTEM EFFICIENCY WITH CIS-ACTING REGULATORY ELEMENTS
The present invention is a synthetic nucleic acid composition comprising: i) a sequence encoding a CRISPR-Cas protein, ii) a sequence encoding a reverse transcriptase, and iii) a sequence encoding a cis-acting regulatory element, and methods of use thereof.
Engineered Cas9 protein variants and systems, nucleic acids encoding said protein variants and systems, and methods of making and using said protein variants and systems for genome modification.
Bioink formulations including an ionically crosslinkable polymer; the ionically crosslinkable polymer includes a plurality of ionically crosslinkable groups, preferably, anionic functional groups. Also provided are bioink formulation kits including the ionically crosslinkable polymers and a cationic crosslinker, wherein the crosslinker, when contacted with the bioink formulation, reacts with the ionically crosslinkable functional group of the ionically crosslinkable polymer to form a polymer network structure.
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
Nuclear targeting tags having a phenylboronate targeting moiety, a linker, a chemically linkable end group suitable for linking the targeting moiety to a molecule of interest, and optionally a spacer between the linker and chemically linkable end group. Also provided are compounds including the nuclear targeting tag covalently bonded to a molecule of interest, such as a drug, probe, dye, peptide, protein, drug candidate, or natural product. Also provided are methods of introducing a molecule of interest into a nucleus of a cell using the nuclear targeting tag. Also provided are methods for preparing the nuclear targeting tags.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Methods for primer switching during amplification reactions are provided. In particular, methods are provided for converting single primer PCR amplicons to dual primer PCR amplicons.
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
35.
NOVEL FERROCENE-BASED UNSYMMETRICAL LIGANDS BEARING BULKY DI(ADAMANTLY)PHOSPHINO MOTIF AND THEIR METAL CATALYSTS
22sp2sp3sp3 coupling and other conventional cross-coupling applications, while being scalable so that they can be provided in sufficient quantity and purity for industrial applications.
Methods for integrating exogenous sequences in genomic loci, wherein the integration is stable and the exogenous sequence can function predictably and reliably.
New methods for preparing solid phase microextraction (SPME) coatings. The process provided involves immersing an SPME coating in water for a time sufficient to form the coating film. The new methods provide SPME coatings with improved consistency in extraction efficiency.
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
B01J 20/281 - Absorbants ou adsorbants spécialement adaptés pour la chromatographie préparative, analytique ou de recherche
An improved device for solid phase microextraction, the device including a plastic substrate, a pre-coating layer on the plastic substrate, and an SPME coating on the precoating layer. SPME coatings are typically incompatible with plastic substrates due to differences between the surface energies of the substrate and the coating, leading to uneven coating and poor adhesion. The addition of the precoating layer provides increased evenness and stronger adhesion of the SPME coating to the plastic substrate. Also provided are method of coating an SPME coating on a plastic substrate, the method including the step of precoating the plastic substrate to provide a precoated substrate and then coating the precoated substrate with an SPME coating, wherein precoating provides improved coating evenness and adhesion of the SPME coating to the plastic substrate.
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
Improved methods for drying for bio-compatible solid phase microextraction (BioSPME) coatings yielding coatings with highly consistent extraction efficiency and biocompatibility. The methods, adapted to flow-through drying systems involve determining relative humidity in and around the drying system, determining a drying temperature range based on the relative humidity, and maintaining the drying temperature within the determined range while drying the coating.
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
A system, software application and method that allows a customer to protect their proprietary database of compounds and substances while utilizing a retrosynthesis software application is disclosed. The customer's proprietary database is encrypted prior to being provided to the retrosynthesis system. This encrypted is performed using a hash and optionally a salt. The retrosynthesis algorithm then creates synthons as is traditionally done. However, after their creation, the synthons are hashed so that they may be compared to the entries in the customer's proprietary database. In this way, the actual contents of the customer's database are never made available to the retrosynthesis system or software application.
G16C 60/00 - Science informatique des matériaux, c.-à-d. TIC spécialement adaptées à la recherche des propriétés physiques ou chimiques de matériaux ou de phénomènes associés à leur conception, synthèse, traitement, caractérisation ou utilisation
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
G16C 20/90 - Langages de programmationArchitectures informatiquesSystèmes de bases de donnéesStockage de données
Methods for preparing a polyene macrolide antifungal with improved aqueous solubility. The method involves providing a polyene macrolide antifungal having a carboxylic acid group; activating the carboxylic acid group; introducing a primary amine to the activated polyene macrolide antifungal; reacting for a time sufficient to convert the carboxylic acid to an amide, and quenching the reaction, thus yielding a polyene macrolide amide or salt thereof. Also provided are water-soluble polyene macrolide derivatives.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
C07H 17/08 - Hétérocycles d'au moins huit chaînons, p. ex. érythromycines
Water-based antifungal composition having improved bioavailability; such formulations include a polyene macrolide antifungal agent, such as nystatin, a surfactant, a buffer, an organic amine base; and water. Also provided are methods for preparing water-based antifungal compositions.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
47.
HPLC carbon with narrow particle size distribution
Methods for producing porous graphic carbon microspheres having improved separation properties over conventional porous graphitic carbons. The methods include dispersing a monovinyl aromatic monomer, a polyvinyl aromatic monomer, and an initiator in a solvent, contacting porous silica microspheres with the monomer dispersion for a time sufficient for the monomers to coat the porous silica microspheres, polymerizing the monomers to form copolymer coated microspheres, sulfonating the copolymer, pyrolyzing the sulfonated copolymer, digesting the carbon microspheres to dissolve the silica leaving porous carbon microspheres, pyrolyzing the porous carbon microspheres, and graphitizing the porous carbon microspheres to form porous graphitic carbon microspheres. Further provided are improved porous graphitic carbon microspheres and chromatography columns including the improved porous graphitic carbon microspheres described herein.
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
C12N 9/96 - Stabilisation d'une enzyme par formation d'un adduct ou d'une compositionFormation de conjugaisons d'enzymes
49.
Poloxamer compositions and methods of making and using same
C08L 71/00 - Compositions contenant des polyéthers obtenus par des réactions créant une liaison éther dans la chaîne principaleCompositions contenant des dérivés de tels polymères
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
50.
HIGH FIDELITY SPCAS9 NUCLEASES FOR GENOME MODIFICATION
Engineered Cas9 protein variants and systems, nucleic acids encoding said protein variants and systems, and methods of making and using said protein variants and systems for genome modification.
Methods for making a dolastatin, auristatin or related compounds comprising the steps of providing a universal dolastatin core of Formula (I) reacting the C-terminal carboxylic acid group with an amine (A) to form an amide bond and reacting the N-terminal amine with a carboxylic acid (CA) to form an amide bond, wherein the steps can be performed in either order. Also provided are an isolated salt of the universal dolastatin core for use in preparation of dolastatins, auristatins and related compounds. Also provided are a number of intermediates and process steps which are useful for the preparation of high purity dolastatin core and high purity dolastatin and auristatin compounds.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
C07C 211/35 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné saturé contenant uniquement des cycles non condensés
C07C 211/63 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone acycliques
C07C 271/22 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes carboxyle
C07D 207/08 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés aux atomes de carbone du cycle
C07K 5/062 - Dipeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
52.
EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE
Methods for making a dolastatin, auristatin or related compounds comprising the steps of providing a universal dolastatin core of Formula (I) reacting the C-terminal carboxylic acid group with an amine (A) to form an amide bond and reacting the N-terminal amine with a carboxylic acid (CA) to form an amide bond, wherein the steps can be performed in either order. Also provided are an isolated salt of the universal dolastatin core for use in preparation of dolastatins, auristatins and related compounds. Also provided are a number of intermediates and process steps which are useful for the preparation of high purity dolastatin core and high purity dolastatin and auristatin compounds.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
C07K 5/062 - Dipeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
C07C 211/35 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné saturé contenant uniquement des cycles non condensés
C07C 211/63 - Composés d'ammonium quaternaire ayant des atomes d'azote quaternisés liés à des atomes de carbone acycliques
C07C 271/22 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des groupes carboxyle
C07D 207/08 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés aux atomes de carbone du cycle
53.
HIGH FIDELITY SPCAS9 NUCLEASES FOR GENOME MODIFICATION
Engineered Cas9 protein variants and systems, nucleic acids encoding said protein variants and systems, and methods of making and using said protein variants and systems for genome modification.
Processes for producing recombinant proteins having low levels of residual host cell proteins. The processes comprise utilizing engineered host cell lines in which specific host cell proteins are tagged with purification tags, wherein the purification tags can be used to remove those specific host cell proteins from the recombinant proteins.
The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
C12N 9/96 - Stabilisation d'une enzyme par formation d'un adduct ou d'une compositionFormation de conjugaisons d'enzymes
The present invention provides methods for modifying chromosomal sequences. In particular, methods are provided for using RNA-guided endonucleases or modified RNA-guided endonucleases to modify targeted chromosomal sequences.
Methods are provided herein for identifying rare and/or unknown DNA sequences by next-generation sequencing approaches. Isolated double-stranded (ds), single-stranded (ss), or ds/ss DNA is fragmented and the fragments are polished, phosphorylated, and tailed, as necessary. Fragmentation can be enzymatic or mechanical. A universal adapter sequence is ligated to each fragment, wherein the adapter can have a top strand without a 5′ phosphate, a 3′ with an —H in place of the —OH, and/or a 3′ extra base complementary to any base added to the polished fragments. The ligatamers may then serve as templates for amplification using a forward primer complementary to the adapter sequence and a reverse primer targeted to the fragment sequence. Compositions produced by these methods and kits adapted for performing these methods are also described herein.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 20/04 - Identification des éléments d'une bibliothèque au moyen d'une étiquette, d'un marqueur ou d'un autre identificateur lisible ou détectable, p. ex. procédés de décodage
Compositions and methods for genome editing of Bacteroides species are provided herein. RNA-guided nucleobase modification systems are engineered to target specific loci in chromosomal DNA of a target bacteria cell, wherein the genome of the target bacterial cell can be modified.
Compositions and methods for genome editing of Bacteroides species are provided herein. RNA-guided nucleobase modification systems are engineered to target specific loci in chromosomal DNA of a target bacteria cell, wherein the genome of the target bacterial cell can be modified.
Compositions and methods for genome editing of Bacteroides species are provided herein. RNA-guided nucleobase modification systems are engineered to target specific loci in chromosomal DNA of a target bacteria cell, wherein the genome of the target bacterial cell can be modified.
C07K 14/205 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Campylobacter (G)
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
63.
MODULATION OF MICROBIOTA COMPOSITIONS USING TARGETED NUCLEASES
Compositions and methods for remodeling complex populations of microbes are provided herein. RNA-guided nuclease systems are engineered to target sites in chromosomal DNA of a targeted prokaryotic, wherein the level of targeted prokaryote can be modulated in a mixed population of prokaryotes.
Compositions and methods for remodeling complex populations of microbes are provided herein. RNA-guided nuclease systems are engineered to target sites in chromosomal DNA of a targeted prokaryotic, wherein the level of targeted prokaryote can be modulated in a mixed population of prokaryotes.
Compositions and methods for remodeling complex populations of microbes are provided herein. RNA-guided nuclease systems are engineered to target sites in chromosomal DNA of a targeted prokaryotic, wherein the level of targeted prokaryote can be modulated in a mixed population of prokaryotes.
A system, software application and method that allows a customer to protect their proprietary database of compounds and substances while utilizing a retrosynthesis software application is disclosed. The customer's proprietary database is encrypted prior to being provided to the retrosynthesis system. This encrypted is performed using a hash and optionally a salt. The retrosynthesis algorithm then creates synthons as is traditionally done. However, after their creation, the synthons are hashed so that they may be compared to the entries in the customer's proprietary database. In this way, the actual contents of the customer's database are never made available to the retrosynthesis system or software application.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/536 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide
G01N 33/537 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec séparation du complexe immunologique de l'antigène ou de l'anticorps non liés
67.
Using nucleosome interacting protein domains to enhance targeted genome modification
Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Methods and kits for detecting and/or quantitating target proteins in biological samples. In particular, the method comprises capture and immobilization of the target protein, protein denaturation, proteolytic digestion, and analysis using a mass spectrometry-based technique.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/563 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des fragments d'anticorps
G01N 33/538 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec séparation du complexe immunologique de l'antigène ou de l'anticorps non liés par colonne, particules ou bande de résine synthétique absorbantes ou adsorbantes
G01N 33/549 - Support organique avec un antigène ou un anticorps emprisonnés dans le support
Spherical carbon nanoparticles having diameters in the range from about 200 to about 900 nm and methods of making the same. According the methods provided herein, spherical nanopolymers are formed through a miniemulsion process, the spherical nanopolymers are polysulfonated then pyrolyzed to form spherical carbon nanoparticles. The surfaces may be further modified with, e.g., various adsorbents to further modify the properties. The formation process allows production of various pore structures, from non-porous to fully porous, with the tunability of pore structure allowing micropores, mesopores, macropores, and combinations of any of the foregoing, allowing for a wide range of surface areas making these nanocarbons suitable for many applications, including sample and bulk preparation, purification, and analysis, and drug delivery applications.
Engineered Cas9 systems that utilize alternate protospacer adjacent motifs for target DNA binding, nucleic acids encoding the engineered Cas9 systems, and methods of using the engineered Cas9 systems for modifying target chromosomal sequences in eukaryotic cells.
Traditional transgene integration methods have led to unstable cell lines and clonal populations that are markedly diverse for expression of the same molecule in terms of expression level and protein heterogeneity. Site-specific targeted integration of transgenes is desired for recombinant therapeutic protein expression. Ex vivo methods for stable integration of exogenous sequences into genomic DNA of a cell are herein provided, the methods including integration of exogenous sequences into for example region bp 1,090,000 to bp 1,127,000 of NCB! Reference Sequence NW 003613934.1.
Methods for integrating exogenous sequences in genomic loci, wherein the integration is stable and the exogenous sequence can function predictably and reliably.
Engineered Cas9 systems are disclosed herein. For example, Cas9-marker fusion proteins are provided. Peptide linkers which facilitate fusion of heterologous proteins to CRISPR proteins in ways that preserve CRISPR functionality are also provided.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/205 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Campylobacter (G)
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
Water-based antifungal composition having improved bioavailability; such formulations include a polyene macrolide antifungal agent, such as nystatin, a surfactant, a buffer, an organic amine base; and water. Also provided are methods for preparing water-based antifungal compositions.
A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
Methods for preparing a polyene macrolide antifungal with improved aqueous solubility. The method involves providing a polyene macrolide antifungal having a carboxylic acid group; activating the carboxylic acid group; introducing a primary amine to the activated polyene macrolide antifungal; reacting for a time sufficient to convert the carboxylic acid to an amide, and quenching the reaction, thus yielding a polyene macrolide amide or salt thereof. Also provided are water-soluble polyene macrolide derivatives.
Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Polymeric adsorbents useful for solid phase extraction (SPE) comprising a copolymer formed by copolymerizing at least one hydrophobic monomer including divinylbenzene and at least one hydrophilic monomer including acrylonitrile are provided. Also provided are SPE cartridges including a divinylbenzene-acrylonitrile hydrophilic-lipophilic balance adsorbent. Further provided are methods of using a divinylbenzene-acrylonitrile hydrophilic-lipophilic balance adsorbent in conventional and simplified SPE techniques.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
Methods for reversibly forming graphene oxide gels by reacting graphene oxide dispersed in an aqueous solution with organic amines or quaternary phosphonium salts. Also provided are methods of forming anhydrous graphene oxide dispersions.
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
C01B 32/192 - Préparation par exfoliation à partir d’oxydes graphitiques
H01G 11/32 - Électrodes caractérisées par leur matériau à base de carbone
H01M 4/133 - Électrodes à base de matériau carboné, p. ex. composés d'intercalation du graphite ou CFx
82.
DOWN-REGULATION OF THE CYTOSOLIC DNA SENSOR PATHWAY
Heteroatomic hole transport materials are provided. The hole transport materials include a non-carbon core: two, four, or eight aromatic groups covalently bound to the non-carbon core; a. terminal substituted diphenylamine end unit on each aromatic group: and optionally aromatic linker groups linking the aromatic groups and the substituted diphenylamine end units. In some embodiments the non-carbon core is non-carbon central atom such as Si, Ge, B-, P+ Sn or Pb. In other embodiments, the non-carbon core is a cubic silsesquioxane. Also provided are methods for making these materials. The materials are particularly useful as hole transport materials in perovskite solar cells.
Methods and kits for detecting and/or quantitating target proteins in biological samples. In particular, the method comprises capture and immobilization of the target protein, protein denaturation, proteolytic digestion, and analysis using a mass spectrometry-based technique.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
85.
ENGINEERED CELLS WITH MODIFIED HOST CELL PROTEIN PROFILES
Mammalian cell lines genetically engineered to have reduced or eliminated expression of specific host cell proteins, and methods for using the engineered mammalian cell lines for the production of recombinant proteins having low levels of residual host cell protein contamination.
Processes for producing recombinant proteins having low levels of residual host cell proteins. The processes comprise utilizing engineered host cell lines in which specific host cell proteins are tagged with purification tags, wherein the purification tags can be used to remove those specific host cell proteins from the recombinant proteins.
Paired CRISPR nickase ribonucleoproteins engineered to target immune-related genomic loci and methods of using said ribonucleoproteins to modify the immune- related genomic loci.
Engineered Cas9 systems that utilize alternate protospacer adjacent motifs for target DNA binding, nucleic acids encoding said engineered Cas9 systems, and methods of using said engineered Cas9 systems for modifying target chromosomal sequences in eukaryotic cells.
Engineered Cas9 systems that utilize alternate protospacer adjacent motifs for target DNA binding, nucleic acids encoding said engineered Cas9 systems, and methods of using said engineered Cas9 systems for modifying target chromosomal sequences in eukaryotic cells.
Engineered Cas9 systems that utilize alternate protospacer adjacent motifs for target DNA binding, nucleic acids encoding the engineered Cas9 systems, and methods of using the engineered Cas9 systems for modifying target chromosomal sequences in eukaryotic cells.
Methods for primer switching during amplification reactions are provided. In particular, methods are provided for converting single primer PCR amplicons to dual primer PCR amplicons.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
93.
Using programmable DNA binding proteins to enhance targeted genome modification
Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
C07H 1/08 - SéparationPurification à partir de produits naturels
C12Q 1/6804 - Analyse d’acides nucléiques utilisant des immunogènes
96.
Methods for next generation genome walking and related compositions and kits
Methods are provided herein for identifying rare and/or unknown DNA sequences by next-generation sequencing approaches. Isolated double-stranded (ds), single-stranded (ss), or ds/ss DNA is fragmented and the fragments are polished, phosphorylated, and tailed, as necessary. Fragmentation can be enzymatic or mechanical. A universal adapter sequence is ligated to each fragment, wherein the adapter can have a top strand without a 5′ phosphate, a 3′ with an —H in place of the —OH, and/or a 3′ extra base complementary to any base added to the polished fragments. The ligatamers may then serve as templates for amplification using a forward primer complementary to the adapter sequence and a reverse primer targeted to the fragment sequence. Compositions produced by these methods and kits adapted for performing these methods are also described herein.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 20/04 - Identification des éléments d'une bibliothèque au moyen d'une étiquette, d'un marqueur ou d'un autre identificateur lisible ou détectable, p. ex. procédés de décodage
de novode novo synthesis of polynucleotides in which 3'-O-reversibly blocked nucleotides are attached to a solid support in the presence of an X family DNA polymerase and in the absence of a nucleic acid template.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
Modified X family DNA polymerases engineered to be capable of incorporating 3'-O-blocked nucleotide 5'-triphosphates during template-independent polynucleotide synthesis, and methods for synthesizing polynucleotides using said modified X family DNA polymerases.
Polymeric adsorbents useful for solid phase extraction (SPE) comprising a copolymer formed by copolymerizing at least one hydrophobic monomer including divinylbenzene and at least one hydrophilic monomer including acrylonitrile. Also provided are SPE cartridges including a divinylbenzene-acrylonitrile hydrophilic-lipophilic balance adsorbent. Further provides are methods of using a divinylbenzene-acrylonitrile hydrophilic-lipophilic balance adsorbent in conventional and simplified SPE techniques.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
An apparatus for simultaneously extracting one or more analytes from a plurality of samples, the apparatus comprising a housing having an upper platform having a plurality of pins, each pin suitable for BioSPME, and a lower platform having a plurality of wells for sample solutions, such when the upper platform is fitted over the lower platform, the pins of the upper platform fit into the wells of the lower platform such that the pins are immersed into the samples, allowing for simultaneous extraction of analytes in each sample. The apparatus can be coupled with other instruments to enable measurement of total and free analytes in each sample. Also provided are methods of simultaneous extraction of analytes in a plurality of samples using the apparatus described herein.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
